| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CONCISE REVIEW |
a INSERM U80, Hôpital E. Herriot, Lyon, France;
b The La Jolla Institute for Allergy and Immunology, La Jolla, California, USA
Key Words. Vav • Hematopoietic cell • Antigen receptor • Signal transduction • Ras • Protein tyrosine kinase • Guanine nucleotide exchange • Dbl-homology
Dr. Amnon Altman, La Jolla Institute for Allergy and Immunology, 11149 North Torrey Pines Road, La Jolla, CA 92037, USA.
Vav, a 95 kDa proto-oncogene product expressed specifically in hematopoietic cells, was originally isolated as a transforming human oncogene. Vav contains an array of functional domains that are involved in interactions with other proteins and, possibly, with lipids. These include, among others, a putative guanine nucleotide exchange domain, a cysteine-rich region similar to the phorbol ester/diacylglycerol-binding domain of protein kinase C, a pleckstrin-homology domain, and Src-homology 2 and 3 (SH2 and SH3, respectively) domains. The presence of these domains, the transforming activity of the vav oncogene, and the rapid increase in tyrosine phosphorylation of Vav induced by triggering of diverse receptors indicate that it plays an important role in hematopoietic cell signaling pathways. Such a role is supported by recent studies using "knockout" mice and transiently transfected T cells, in which Vav deletion or overexpression, respectively, had marked effects on lymphocyte development or activation. The presence of a putative guanine nucleotide exchange domain, the prototype of which is found in the dbl oncogene product, implies that Vav functions as a guanine nucleotide exchange factor (GEF) for one (or more) members of the Ras-like family of small GTP-binding proteins. In support of such a role, Vav preparations were found in some (but not other) studies to mediate in vitro-specific GEF activity for Ras. Additional studies are required to identify the physiological regulators and targets of Vav, and its exact role in hematopoietic cell development and signaling.
This article has been cited by other articles:
|
|
 |
|
  B. J. Irvin, B. L. Williams, A. E. Nilson, H. O. Maynor, and R. T. Abraham Pleiotropic Contributions of Phospholipase C-gamma 1 (PLC-gamma 1) to T-Cell Antigen Receptor-Mediated Signaling: Reconstitution Studies of a PLC-gamma 1-Deficient Jurkat T-Cell Line Mol. Cell. Biol., December 15, 2000; 20(24): 9149 - 9161. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Galandrini, G. Palmieri, M. Piccoli, L. Frati, and A. Santoni Role for the Rac1 Exchange Factor Vav in the Signaling Pathways Leading to NK Cell Cytotoxicity J. Immunol., March 15, 1999; 162(6): 3148 - 3152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Nishina, C Vaz, P Billia, M Nghiem, T Sasaki, J. De la Pompa, K Furlonger, C Paige, C Hui, K. Fischer, et al. Defective liver formation and liver cell apoptosis in mice lacking the stress signaling kinase SEK1/MKK4 Development, January 2, 1999; 126(3): 505 - 516. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Michel, L. Grimaud, L. Tuosto, and O. Acuto Fyn and ZAP-70 Are Required for Vav Phosphorylation in T Cells Stimulated by Antigen-presenting Cells J. Biol. Chem., November 27, 1998; 273(48): 31932 - 31938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Gewirtz, D. L. Sokol, and M. Z. Ratajczak Nucleic Acid Therapeutics: State of the Art and Future Prospects Blood, August 1, 1998; 92(3): 712 - 736. [Full Text] [PDF]
|
|
|
|
|
|
S. Ogilvy, A. G. Elefanty, J. Visvader, M. L. Bath, A. W. Harris, and J. M. Adams Transcriptional Regulation of vav, a Gene Expressed Throughout the Hematopoietic Compartment Blood, January 15, 1998; 91(2): 419 - 430. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
